The $572 million in damages that an Oklahoma judge purchased Johnson & Johnson to pay on Monday for its function in the state’s opioid crisis will more than likely seem like a slap on the wrist for the significant corporation.

The great total up to simply 3.7% of the business’s net revenue for 2018, according to SEC filings

In reality, journalism around the great appears to have had a favorable result on the business. After the fine was revealed on Monday, J&J stock in fact increased more than 5% in aftermarket trading

Judge Thad Balkman of the Cleveland County District Court in Norman, Oklahoma, agreed the state’s chief law officer, Mike Hunter, who argued that Johnson & Johnson’s marketing practices sustained the opioid epidemic by flooding the marketplace with pain relievers.

Christine Gagnon holds an indication throughout a demonstration with others who have actually lost enjoyed ones to OxyContin and opioid overdoses, outside the Purdue Pharma head office in Stamford, Connecticut on Aug. 17, 2018.
Associated Press

Learn More: Drugmaker Johnson & Johnson was simply purchased to pay $572 million for its function in the opioid epidemic

The business stated in a declaration to Organisation Expert that it prepares to appeal the judgement.

Hunter had actually desired Johnson & Johnson to pay more than $17 billion to assist the state address the epidemic for the next 30 years, through dependency treatment and avoidance programs.

The quantity the business was in fact fined will cover the state’s strategy to eliminate the epidemic for one year.

Johnson & Johnson produces the pain relievers Duragesic and Nucynta.